BNGO — BioNano Genomics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapValue Trap

Annual cashflow statement for BioNano Genomics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	R2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-41.1	-72.4	-133	-232	-112
Depreciation
Deferred Taxes
Non-Cash Items	4.75	10.6	24.8	90.9	30.7
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-3.44	-7.65	-28.6	2.48	-1.83
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Other Operating Cash Flow
Cash from Operating Activities	-38.3	-71.9	-125	-125	-68.9
Capital Expenditures	0	-0.822	-2.41	-1.69	-0.103
Purchase of Fixed Assets
Other Investing Cash Flow Items	-2.45	-277	85.2	25.8	73.9
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-2.45	-278	82.8	24.2	73.8
Financing Cash Flow Items	-2	-1.7	-0.428	-14.9	-10.1
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	61.9	336	23	114	-13.7
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	21.1	-13.9	-19.1	12.9	-8.78